SeQure DX On-Target and Off-Target Editing Assessment Services SeQure DX Comprehensive Suite of On-target and Off-target Assessment Assays

SeQure logos_Rev-full color

Comprehensive Suite of On-Target and Off-Target Assessment Assays

Our comprehensive off-target gene editing assessment platform integrates screening, nomination and confirmation assays, providing unmatched precision in guide RNA selection and off-target risk assessment. By addressing safety and regulatory expectations early, our platform reduces development risks, streamlines therapeutic design, and accelerates your path to the clinic with confidence and efficiency.

Request a consultation

A comprehensive portfolio of gene-editing assays

Summary-table
SeQure logos_screening-icon

Screening assays

Preview of off-target risk for informed guide selection

Guide Profiler™

In silico preview of potential off-target effects associated with your gene editing tool. Enables you to start your gene editing risk assessment by rapidly screening sgRNAs to understanding on-target efficacy and off-target editing risks.

Guide Select™

Off-target assessment assay designed for screening multiple guide RNAs in parallel. Variant-aware searching within a limited search space enables high-powered, low-cost risk assessment for guide RNA selection.

SeQure logos_nomination-icon

Nomination assays

Comprehensive off-target assessment

ONE-seq™

Gold standard population-scale, variant-aware, off-target detection. Candidate off-target enumeration, enrichment and biochemical in vitro cutting combined with deep sequencing enables high-sensitivity detection of low-frequency off-target events. 

DEUX-seq™

Orthogonal approach to supplement ONE-seq off-target nomination. Unbiased, biochemical, off-target editing assay provides a complementary approach to supplement your off-target risk assessment efforts. 

GUIDE-seq™

Orthogonal approach to supplement ONE-seq off-target nomination. Unbiased, cell-based, off-target editing assay provides a complementary approach to supplement your off-target risk assessment efforts.  

SeQure logos_confirmation-icon

Confirmation assays

Verifies cellular edits and structural rearrangements

Amplicon-seq™

High-sensitivity confirmation of off-target effects in your cell type of interest post-editing. Informed by nomination assays, NGS pinpoints off-target edits with resolution down to exact genomic coordinates.

SAFER Detection™

High-sensitivity confirmation of structural rearrangements in your cell type of interest post-editing. NGS interrogation allows for resolution down to exact genomic coordinates. 

Resources

Visualizations of the three candidate off-target sites with high ONE-seq scores that are present on the same chromosome as the on-target locus. PCSK9-1 has the lowest risk
Poster
ONE-seq for Variant-Aware Therapeutic Guide Selection
Breakpoint site alignment. The reference CCR5 target site is shown at the top. Mismatched nucleotides and indels are highlighted. The alignment score is listed on the right. Diamonds indicate off-target sites detected at validated inter-chromosomal translocation breakpoints.
Poster
SAFER Detection for Efficient Interrogation of DNA Rearrangements in Gene-Edited Human Cells
A table for guides that then lists off-target score (by MIT and CFD), Activity (CRISPRater), number of loci (L. Distance, and Risk Profiler number.
Poster
Guide Profiler: A Genetic Variant-Aware Computational Tool for Improved Guide RNA Selection for CRISPR-Based Therapeutic Applications
View all resources

Ready to learn more?

Request a consultation
Young female scientist filling chemical through pipette while working in laboratory